Soleno Therapeutics (SLNO) Other Non-Current Assets (2014 - 2026)
Soleno Therapeutics (SLNO) reported Other Non-Current Assets of $163000.0 for Q1 2026, up 96.39% year-over-year from $83000.0 in Q1 2025, and little changed quarter-over-quarter from $163000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 13 years of Other Non-Current Assets data on file, last reported at $163000.0 in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $163000.0, up 96.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $163000.0 (up 96.39% YoY), and the FY2025 annual result was $163000.0, up 96.39% from the prior year.
- Other Non-Current Assets was little changed at $163000.0 in Q1 2026 per SLNO's latest filing, from $163000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $165000.0 in Q2 2023 and troughed at $40000.0 in Q1 2022.
- A 5-year average of $117857.1 and a median of $104500.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets surged 215.0% in 2023, then sank 49.7% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $40000.0 in 2022, then surged by 312.5% to $165000.0 in 2023, then slumped by 49.7% to $83000.0 in 2024, then soared by 96.39% to $163000.0 in 2025, then changed by 0.0% to $163000.0 in 2026.
- Business Quant data shows SLNO's Other Non-Current Assets at $163000.0 in Q1 2026, $163000.0 in Q4 2025, and $83000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 163,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 163,000.00 |
| Dec 31, 2025 | 163,000.00 |
| Sep 30, 2025 | 83,000.00 |
| Jun 30, 2025 | 83,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | 165,000.00 |
| Dec 31, 2023 | 165,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Jun 30, 2023 | 165,000.00 |
| Mar 31, 2023 | 126,000.00 |
| Mar 31, 2022 | 40,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 40,000.00 |
| Dec 31, 2020 | 15,000.00 |
| Mar 31, 2020 | 59,000.00 |
| Dec 31, 2019 | 59,000.00 |